A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias

Arun R Panigrahi, Amy Clark, John Myers, Ashok Raj

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Successful treatment of both pediatric autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP), specifically those that are refractory to first-line therapies, remains unsatisfactory in terms of long-term remission and medication side effects. Here, we propose a novel combination therapy of mycophenolate mofetil (MMF), an adjunct immunosuppressive, and short-term corticosteroids for the treatment of persistent or chronic autoimmune cytopenias in children. This combination may allow for rapid decrease of steroid usage as well as prolonged count stabilization with minimal toxicity to the patient. Procedure: Prospective case series of nine patients, six with persistent or chronic ITP and three with persistent or chronic AIHA, between the ages of 5 and 19 years who are being treated with combination therapy consisting of corticosteroids and MMF. Results: All patients with ITP (Patients 4–9) and AIHA (Patients 1–3) met complete response (CR) criteria, as they all initially achieved platelet counts 100 × 109 l–1 or more or hemoglobin level greater than or equal to 10 g/dl, respectively, while on combination therapy and then maintained this level or higher while on MMF alone after steroids were discontinued. Conclusions: Our results are very promising, as MMF appears to be an effective and well-tolerated adjunct immunosuppressant that allows for rapid weaning of steroid usage, minimal adverse side effects to the patients, and long-term stabilization of counts, a goal that has not been achieved successfully with other secondary treatment modalities. Therefore, this novel combination therapy may be an excellent alternative for the treatment of persistent or chronic autoimmune cytopenias in the pediatric population.

Original languageEnglish (US)
Pages (from-to)287-293
Number of pages7
JournalPediatric Blood and Cancer
Volume64
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Mycophenolic Acid
Adrenal Cortex Hormones
Pediatrics
Autoimmune Hemolytic Anemia
Idiopathic Thrombocytopenic Purpura
Therapeutics
Steroids
Immunosuppressive Agents
Weaning
Platelet Count
Hemoglobins

Keywords

  • autoimmune hemolytic anemia
  • corticosteroids
  • immune thrombocytopenic purpura
  • mycophenolate mofetil

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias. / Panigrahi, Arun R; Clark, Amy; Myers, John; Raj, Ashok.

In: Pediatric Blood and Cancer, Vol. 64, No. 2, 01.02.2017, p. 287-293.

Research output: Contribution to journalArticle

@article{eb7e4bcd6aad46dc8a9adfcc89698891,
title = "A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias",
abstract = "Background: Successful treatment of both pediatric autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP), specifically those that are refractory to first-line therapies, remains unsatisfactory in terms of long-term remission and medication side effects. Here, we propose a novel combination therapy of mycophenolate mofetil (MMF), an adjunct immunosuppressive, and short-term corticosteroids for the treatment of persistent or chronic autoimmune cytopenias in children. This combination may allow for rapid decrease of steroid usage as well as prolonged count stabilization with minimal toxicity to the patient. Procedure: Prospective case series of nine patients, six with persistent or chronic ITP and three with persistent or chronic AIHA, between the ages of 5 and 19 years who are being treated with combination therapy consisting of corticosteroids and MMF. Results: All patients with ITP (Patients 4–9) and AIHA (Patients 1–3) met complete response (CR) criteria, as they all initially achieved platelet counts 100 × 109 l–1 or more or hemoglobin level greater than or equal to 10 g/dl, respectively, while on combination therapy and then maintained this level or higher while on MMF alone after steroids were discontinued. Conclusions: Our results are very promising, as MMF appears to be an effective and well-tolerated adjunct immunosuppressant that allows for rapid weaning of steroid usage, minimal adverse side effects to the patients, and long-term stabilization of counts, a goal that has not been achieved successfully with other secondary treatment modalities. Therefore, this novel combination therapy may be an excellent alternative for the treatment of persistent or chronic autoimmune cytopenias in the pediatric population.",
keywords = "autoimmune hemolytic anemia, corticosteroids, immune thrombocytopenic purpura, mycophenolate mofetil",
author = "Panigrahi, {Arun R} and Amy Clark and John Myers and Ashok Raj",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/pbc.26210",
language = "English (US)",
volume = "64",
pages = "287--293",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias

AU - Panigrahi, Arun R

AU - Clark, Amy

AU - Myers, John

AU - Raj, Ashok

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: Successful treatment of both pediatric autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP), specifically those that are refractory to first-line therapies, remains unsatisfactory in terms of long-term remission and medication side effects. Here, we propose a novel combination therapy of mycophenolate mofetil (MMF), an adjunct immunosuppressive, and short-term corticosteroids for the treatment of persistent or chronic autoimmune cytopenias in children. This combination may allow for rapid decrease of steroid usage as well as prolonged count stabilization with minimal toxicity to the patient. Procedure: Prospective case series of nine patients, six with persistent or chronic ITP and three with persistent or chronic AIHA, between the ages of 5 and 19 years who are being treated with combination therapy consisting of corticosteroids and MMF. Results: All patients with ITP (Patients 4–9) and AIHA (Patients 1–3) met complete response (CR) criteria, as they all initially achieved platelet counts 100 × 109 l–1 or more or hemoglobin level greater than or equal to 10 g/dl, respectively, while on combination therapy and then maintained this level or higher while on MMF alone after steroids were discontinued. Conclusions: Our results are very promising, as MMF appears to be an effective and well-tolerated adjunct immunosuppressant that allows for rapid weaning of steroid usage, minimal adverse side effects to the patients, and long-term stabilization of counts, a goal that has not been achieved successfully with other secondary treatment modalities. Therefore, this novel combination therapy may be an excellent alternative for the treatment of persistent or chronic autoimmune cytopenias in the pediatric population.

AB - Background: Successful treatment of both pediatric autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP), specifically those that are refractory to first-line therapies, remains unsatisfactory in terms of long-term remission and medication side effects. Here, we propose a novel combination therapy of mycophenolate mofetil (MMF), an adjunct immunosuppressive, and short-term corticosteroids for the treatment of persistent or chronic autoimmune cytopenias in children. This combination may allow for rapid decrease of steroid usage as well as prolonged count stabilization with minimal toxicity to the patient. Procedure: Prospective case series of nine patients, six with persistent or chronic ITP and three with persistent or chronic AIHA, between the ages of 5 and 19 years who are being treated with combination therapy consisting of corticosteroids and MMF. Results: All patients with ITP (Patients 4–9) and AIHA (Patients 1–3) met complete response (CR) criteria, as they all initially achieved platelet counts 100 × 109 l–1 or more or hemoglobin level greater than or equal to 10 g/dl, respectively, while on combination therapy and then maintained this level or higher while on MMF alone after steroids were discontinued. Conclusions: Our results are very promising, as MMF appears to be an effective and well-tolerated adjunct immunosuppressant that allows for rapid weaning of steroid usage, minimal adverse side effects to the patients, and long-term stabilization of counts, a goal that has not been achieved successfully with other secondary treatment modalities. Therefore, this novel combination therapy may be an excellent alternative for the treatment of persistent or chronic autoimmune cytopenias in the pediatric population.

KW - autoimmune hemolytic anemia

KW - corticosteroids

KW - immune thrombocytopenic purpura

KW - mycophenolate mofetil

UR - http://www.scopus.com/inward/record.url?scp=84988000653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988000653&partnerID=8YFLogxK

U2 - 10.1002/pbc.26210

DO - 10.1002/pbc.26210

M3 - Article

C2 - 27615037

AN - SCOPUS:84988000653

VL - 64

SP - 287

EP - 293

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -